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Clinical Management of Allergic Rhinitis – the Allergy 
Society of South Africa Consensus Update
Inadequately controlled allergic rhinitis in asthmatic patients 
can contribute towards increased exacerbation of asthma, poorer 
medical control and an increased demand on medical resources. 
If properly diagnosed and treated, a significant improvement 
in the patient’s wellbeing and quality of life (QOL) is to be 
expected, with the added bonus of the pharmaco-economic 
benefits that result when allergies are cured.
Since the first comprehensive South African Consensus 
statement,1 there have been several publications on new forms of 
therapy for patients with allergic rhinitis.2-4 The Allergy Society 
highlights advances and recommends the following.
1. Classification of allergic rhinitis
The International Allergic Rhinitis and its Impact on Asthma 
(ARIA) Workshop report, supported by the World Health 
Organization (WHO) and compiled by experts from 16 
countries, was published in the Journal of Allergy and Clinical 
Immunology.2 The ARIA document reclassified allergic rhinitis 
into ‘persistent’ or ‘intermittent’, which may in turn be ‘mild’ 
or ‘moderate-severe’.  This new classification has been accepted 
by the World Allergy Organization and the European Academy 
of Allergy and Clinical Immunology (EAACI) and is now 
applied globally, replacing the old classification of ‘perennial’ 
or ‘seasonal’ rhinitis.  The ARIA classification of allergic rhinitis 
also brought it in line with the Global Initiative for Asthma 
(GINA) classification of asthma, since rhinitis and asthma are 
considered components of the united airways, which share the 
same aetiology and pathology. ‘Intermittent’ refers to rhinitis 
with symptoms lasting less than 4 weeks or for less than 4 days 
per week.  ‘Persistent’ refers to rhinitis lasting more than 4 days 
a week for more than 4 weeks per year.  Mild rhinitis does not 
interfere with sleep, sport, leisure or daily activities.  Moderate 
to severe rhinitis affects sleep, work, daily activities, sport, 
leisure, school or causes troublesome symptoms.3,4
Different pharmacological treatments for mild, moderate or 
severe, intermittent or persistent rhinitis have been assessed 
using evidence-based medicine criteria3,4 and applied to South 
Africa.5
In view of the long pollen seasons in Gauteng and Limpopo 
provinces, the Eastern Cape, the Eastern Free State and the 
Western Cape, most patients who have pollen-induced rhinitis 
have persistent rhinitis.
2. Assessment of rhinitis patients 
should be more comprehensive, and 
include non-nasal symptoms and 
quality of life
Patients with allergic rhinitis typically feel ‘under par’ and are 
troubled by their disease.  The QOL of rhinitis subjects has been 
reported to be worse than that of asthmatics.6  Doctors should 
assess their rhinitis patients holistically rather than just focusing 
on the nose.
The Juniper Rhinoconjunctivitis Quality of Life Questionnaire 
(RQLQ)6 is a validated method of assessing QOL in patients 
with rhinitis and includes the following domains:  activities, 
eye symptoms, nasal problems, practical problems, emotional 
problems, non-hayfever symptoms and sleep.  These are 
scored using a 0 - 6 severity scoring system and provide 
a comprehensive assessment of allergic rhinitis patients. 
Combined with an assessment of their medication requirements, 
QOL scores can be used to calculate a Global Severity Score 
(GSS),7 which may also be used to monitor improvement and 
response to treatment.
3. Investigation of allergy in rhinitis 
patients in South Africa seldom 
requires large investigative panels
Skin-prick testing remains the least expensive method of 
testing and will effectively diagnose the relevant allergies in 
over 80% of allergic rhinitis patients.  A testing panel should 
include house dust mites (Der-p-1, Der-f-1), Bermuda grass, rye 
grass, and cat, dog, cockroach and fungal spores (Cladosporium, 
Alternaria and Aspergillus) in all South African regions, but 
should the history suggest it, plane and oak trees, maize pollen 
(Zea mays), and cypress and eucalyptus could be added.  
Pollen allergies in the Savannah, the Northern Province, 
Mpumalanga and Limpopo Province are invariably because of 
sensitivity to Bermuda, rye and eragrostis grass pollens.
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Some patients with rhinitis are affected by foods. Non-
immunoglobulin E (IgE)-mediated food-induced rhinitis 
appears to be more common than previously thought.  These 
food intolerance reactions are usually accompanied by negative 
specific IgE tests to the relevant allergens.  Some adverse 
reactions are due to preservatives such as sulphites (e.g. in 
wine, beer and soft drinks) that cause nasal stuffiness and other 
symptoms. 
The CAP RAST is a sensitive and specific blood test, and 
a screening panel should include at least house dust mites 
(Der-p-1 and Der-f-1), a grass mix (including Bermuda grass) 
and a mould mix (Cladosporium, Aspergillus and Alternaria).  
Based on history and exposure a further 400 allergens can be 
tested for using CAP RAST (e.g. cat, latex, foods, etc.), but 
these should not form part of routine screening tests unless 
suggested by the history.
The Phadiatop test may be used as a screening blood test 
if no useful history is available to assist in the selection of a 
specific test, or when an inhalant allergy specifically needs 
to be excluded (e.g. in suspected vasomotor rhinitis, or when 
dermatographism is present).
Vasomotor components (e.g. sensitivity to perfumes, 
temperature changes, air-conditioning and diesel fumes) may 
occur in non-allergic rhinitis but may also be present in some 
patients with true allergic rhinitis.
4. Antihistamines
In addition to long-acting second-generation antihistamines 
such as cetirizine, loratadine and fexofenadine, which 
are effective and safe, new-generation antihistamines, 
desloratadine and levocetirizine, are available in South Africa. 
They lack sedation, cardiotoxic effects (QT prolongation) 
and interaction with CYP450 enzymes, and nonspecific 
antimuscarinic effects. The old ‘first-generation’ antihistamines 
are not recommended for the treatment of allergic rhinitis 
(e.g. chlorpheniramine, diphenhydramine, hydroxyzine, etc.).   
The sedating effects of antihistamines are less pronounced 
in children than adults.  First-generation antihistamines are 
effective for symptom relief and are the only antihistamines 
currently available in some public-sector institutions.
The sedating effects of first-generation antihistamines may 
be equivalent to those experienced with alcohol consumption8 
and may lead to motor vehicle accidents, poor school 
performance9 and ICU admission for toxicity.  They should 
only be used with due caution when second-generation 
antihistamines are unobtainable, and are better used at night 
and on an ‘as-required’ basis.  Patients must be informed about 
possible sedating effects of these antihistamines when they are 
prescribed.
First-generation antihistamines are present in many 
formulations for the treatment of influenza, cough and pain 
and may cause unexpected and at times severe sedation.5 New-
generation antihistamines have also been shown to have anti-
inflammatory effects, which may be of clinical significance in 
alleviation of the nasal eosinophilia so characteristic of allergic 
rhinitis.
5. Intranasal steroids
Intranasal steroids remain the most potent all-round anti-
inflammatory medications for the management of allergic 
rhinitis patients.  However, proper instruction in their use is 
essential.  The nozzle of the spray should be directed in an 
upward and lateral direction towards the inferior turbinates 
and not towards the nasal septum.  Doses should be kept 
below a total of 400 μg beclomethasone equivalent per patient 
per day to avoid adrenal suppression, particularly in children, 
and special care is required in the case of patients who are also 
taking inhaled steroids for the treatment of asthma. Certain 
steroid drops (e.g. betamethasone) are potent, not usually 
recommended intranasally and should never be used for 
more than 10 days.  Inhaled steroids are safe for long-term use 
and need not be discontinued when patients have an upper 
respiratory tract infection or sinusitis. In patients who also 
require inhaled steroids, doses should be minimised to avoid 
systemic side-effects from higher doses of steroids absorbed 
from the nose and respiratory tract.
6. Injected/oral steroids
Patients who have severe incapacitating disease should be 
assessed carefully before prescribing steroids via any route 
other than the intranasal route.  Severe symptoms may result 
from complications such as infected sinusitis, polyps or 
undiagnosed allergies, and underlying reasons for more severe 
symptoms must be explored, preferably by a specialist.
Injected or oral steroids should only be used for severe 
incapacitating allergic rhinitis in adults for short periods 
(10 days).  Long-term adverse effects of repeated courses of 
intramuscular treatment in the management of allergic rhinitis 
remain a concern.  Some patients, when given injections of 
cortisone, appear cushingoid within 3 months (N Mygind, 
Denmark – personal communication).
A recent study in South Africa10 showed that short-term 
adrenal suppression occurred within 2 weeks of 1 mg 
betamethasone given daily, which was easily reversible on 
discontinuing therapy. Long-term use of steroids by any route 
other than the intranasal route is not recommended. Oral 
and injected steroids should not be used for the treatment of 
paediatric allergic rhinitis.
In exceptional cases short-term oral steroids may be 
used where patients are unresponsive to a combination of 
antihistamines and intranasal steroids.  Celestamine contains a 
first-generation antihistamine and may therefore be sedating. 
Intraturbinate steroid injections are not recommended.
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Oral steroids in combination with sedating antihistamines 
are still widely used and often abused in the treatment of 
allergic rhinitis.  No more than 4 such courses should be used 
per year, since such patients may well have other underlying 
nasal pathology (e.g. polyps, tumours, adenoids), which 
require the assessment of an ENT surgeon.
Patients must be informed that there are steroids in these 
medications and parents should be advised not to ‘self-
medicate’ their children with unused medications.
7. Leukotriene receptor antagonists
With the launch of montelukast for patients in South Africa 
as young as 2 years of age, and its published beneficial effects 
in allergic rhinitis,11,12 its role in the general management 
of rhinitis is being explored.  It has been demonstrated 
that asthmatics who also had concomitant allergic rhinitis 
responded better to montelukast than those who did not suffer 
from allergic rhinitis.12 Therefore montelukast may have a 
special niche as add-on therapy in asthmatics who also have 
allergic rhinitis, since its therapeutic effect has been shown 
to be equivalent to that of loratadine.11 However, leukotriene 
receptor antagonists are less effective than intranasal 
corticosteroids. The combination of a leukotriene receptor 
antagonist and an antihistamine is significantly more effective 
than when either is used alone.13 
Beneficial effects of leukotriene receptor antagonists also 
result from their anti-inflammatory effects on vascular 
permeability, eosinophils, and mucus production. In young 
children with allergic rhinitis and mild asthma it may therefore 
be effective as monotherapy.  Since its clinical effects are 
rapid in onset (within 48 hours), a trial of 14 days is indicated 
and should be reviewed before chronic management is 
recommended for this indication.  In patients who have asthma 
with aspirin sensitivity and nasal polyps (e.g. Samter’s triad), 
montelukast is the drug of choice.
8. Allergen immunotherapy
Specific allergen immunotherapy (SIT) is the only form of 
therapy that can change the natural history of allergic rhinitis, 
prevent progression of disease and cure patients if they 
are selected carefully. Two forms of SIT are available, viz. 
SCIT (subcutaneous immunotherapy) and SLIT (sublingual 
immunotherapy).
Both the sublingual and injected (subcutaneous) routes are 
highly effective for patients with house dust mite allergies or 
grass pollen allergies.14 In the sublingual route patients are 
given increasing concentrations of allergen, held under the 
tongue for 2 minutes before swallowing, for an initial build-up 
phase of 1 month followed by a maintenance course for 2 - 3 
years.
The sublingual route (SLIT) is safer and is conveniently 
taken at home.  It is therefore a suitable ‘safe’ form of 
immunotherapy in areas where specialised services required 
for injection allergy immunotherapy (SCIT), i.e. allergy 
immunotherapy clinics, are not available.
Only doctors who have undergone adequate basic training 
in this procedure should conduct SCIT.  Recently, equivalent 
efficacy was reported for SCIT and SLIT, but SLIT was found to 
be safer.15
A recent Cochrane Review16 showed that SLIT was 
effective and safe for both house dust mite and grass pollen-
monosensitive rhinitis subjects.
Post-marketing studies have shown SLIT to be safe.17,18 No 
serious adverse side-effects were reported in a review of the 
combined experience of the South African Allergic Rhinitis 
Working Group (SAARWG), representing over 200 patients in 
South Africa treated with SLIT for up to 3 years, on a named 
patient basis. Medication costs for patients receiving SLIT ha 
reduced by 75% in South Africa.7
Before undergoing immunotherapy, patients need to have 
skin-prick tests or blood RAST tests to confirm their specific 
allergy and to exclude polysensitisation.
Since immunotherapy vaccines are still unregistered with 
the Medicines Control Council (MCC), they must currently 
be approved by the MCC on a named patient basis before 
ordering and administration. Until SLIT is registered fully 
with the MCC the prescribing doctor is responsible for making 
the application and providing 6-monthly progress reports on 
such patients.  Following approval from the MCC, vaccines 
currently obtained from Alk-Abello (Spain), Stallergenes 
(France) and Leti (Spain) may be used in patients who have the 
correct clinical indications. 
Patients must be carefully instructed regarding the 
indications, administration and possible side-effects of 
immunotherapy before selecting either SLIT or SCIT.  
Treatment must be for a minimum of 3 years, and 6-monthly 
follow-up visits are recommended to assess symptom scores, 
ongoing medication requirements and QOL issues.
SLIT and SCIT dramatically reduce the requirements for 
ongoing therapy with intranasal steroids and antihistamines 
and are therefore cost-effective for selected patients.
Contraindications for SLIT or SCIT include polysensitisation 
to several unrelated allergen groups, older patients (over 
the age of 60 years), patients with thyrotoxicosis, coronary 
vascular disease, mental disorders, autoimmune diseases and 
hypertension.
9. Generic substitution
Although generic substitution of antihistamines and intranasal 
steroids for the treatment of allergic rhinitis is recommended 
by the Health and Pharmacy Act,19 some patients do not do 
well, or improve clinically, on certain generic antihistamines 
and intranasal steroids. Some health funders and state 
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hospitals recommending certain branded generics without 
confirmation of clinical equivalence with the parent drug have 
exacerbated this. Trials showing clinical equivalence should 
be made available before a health provider recommends a 
generic alternative for the purposes of reimbursement.  Where 
such information is not available the parent drug should be 
dispensed wherever possible.
10. Alternative rhinitis treatments
The place of complementary and alternative medicine in the 
treatment of allergic rhinitis has been reviewed.20 There is no 
convincing scientific proof of efficacy for most complementary 
and alternative medicine treatments for rhinitis and asthma.
Patients should be warned that some alternative or herbal 
products may have side-effects, are expensive, and have 
not been shown to be superior in efficacy to evidence-based 
medicines.
11. Education of pharmacists and the 
public
In more than 60% of cases the first line of help for the allergic 
patient is the local pharmacy.  Pharmacists must be educated 
on the diagnosis of ‘allergic’ versus ‘infective’ conditions of 
the nose, to avoid ‘cold mixtures’ and/or antibiotics being 
repeatedly prescribed for patients with allergies.  Over-the-
counter (OTC) intranasal vasoconstrictor drops are dangerous 
if used chronically and lead to resistant rhinitis or rhinitis 
medicamentosa.
Recent ARIA workshop guidelines for the management of 
allergic symptoms in the pharmacy have been published in 
the form of a pocket handbook; these guidelines are endorsed 
by the EAACI and the Royal Pharmaceutical Society of Great 
Britain.21
Wherever possible pharmacists should not recommend 
sedating antihistamines for rhinitis treatment.
The general public should be made aware of how to 
distinguish broadly between symptoms of a cold (e.g. sore 
throat, low-grade fever with rhinorrhoea, headache and 
malaise) from the typical symptoms of allergy (no sore throat, 
no fever, itchy throat, itchy eyes, itchy nose with runny or 
blocked nose, which is persistent for more than 10 days 
and has a seasonal or diurnal variation).  Such symptoms 
necessitate specific allergy testing and specific allergy 
treatment by general practitioners or specialised allergy clinics.
Non-responsive allergic conditions should be referred to a 
specialist so as to diagnose and treat other conditions that may 
mimic or aggravate allergic rhinitis.
The authors thank Lindi Terblanche for secretarial assistance 
and  Professors Eugene Weinberg and Cas Motala for suggesting 
improvements to the manuscript.
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